As Its Stock Gets Set For Upgrade, Boan Biotech Still Faces Two Big Risks
Key Takeaways:
With two products now generating revenue, Boan Biotech will soon have the “B” marker for high-risk tickers removed from its stock symbol
Boan faces stiff competition in its main area of biosimilar drugs, and could also face price pressure if its products are included in China’s centralized drug program
